Podcasts about host jennifer caudle

Host: Jennifer Caudle, DO Guest: Naval Daver, MD Not only is CD123 one of the most common antigens expressed on the surface of acute myeloid leukemia (AML) tumors, but it's also associated with more proliferative disease that's resistant to standard therapies. Given its prevalence and potential implications, a number of different CD123-targeting approaches are under investigation, including antibody-drug conjugates, bi-specific antibodies, fusion protein, and CAR T-cell therapy. In light of these new approaches, Dr. Jennifer Caudle and Dr. Naval Daver discuss the importance of targeting CD123 in AML. Dr. Daver is a Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center in Houston.

Host: Jennifer Caudle, DO Guest: Lori Guyton, MD Guest: Douglas Scharre, MD As our understanding of Alzheimer's disease continues to evolve, it's critical to understand the clinical and pathologic changes underpinning Alzheimer's disease as it may be able to help guide early diagnosis and clinically meaningful management decisions.1 That's why Drs. Douglas Scharre and Lori Guyton speak with Dr. Jennifer Caudle about Alzheimer's disease pathophysiology and how it translates to clinical practice. Dr. Scharre is a Professor of Clinical Neurology and Psychiatry as well as the Director for the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin. Reference: Porsteinsson A, Isaacson R, Knox S, Sabbagh M, Rubino I. Diagnosis of early Alzheimer's disease: Clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371-386. © Eisai Inc. 2024. All Rights Reserved.AD-M2130 November 2024

Host: Jennifer Caudle, DO Guest: Lori Guyton, MD Guest: Douglas Scharre, MD Our understanding of the mechanisms underlying Alzheimer's disease is growing, and these advances can help inform diagnosis and management strategies. In fact, as our understanding of Alzheimer's disease evolves, our strategies to diagnose and manage the disease are changing to focus on early diagnosis and intervention.1 Joining Dr. Jennifer Caudle to discuss our current understanding of disease progression as well as the impact and benefit of diagnosing Alzheimer's disease early are Drs. Douglas Scharre and Lori Guyton. Dr. Scharre is the Director of the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin. Reference: Atri A. The Alzheimer's disease clinical spectrum: Diagnosis and management. Med Clin North Am. 2019;103:263-293. © Eisai Inc. 2024. All Rights Reserved.AD-M2123 November 2024

Host: Jennifer Caudle, DO Guest: Lori Guyton, MD Guest: Douglas Scharre, MD As our understanding of Alzheimer's disease continues to evolve, it's critical to understand the clinical and pathologic changes underpinning Alzheimer's disease as it may be able to help guide early diagnosis and clinically meaningful management decisions.1 That's why Drs. Douglas Scharre and Lori Guyton speak with Dr. Jennifer Caudle about Alzheimer's disease pathophysiology and how it translates to clinical practice. Dr. Scharre is a Professor of Clinical Neurology and Psychiatry as well as the Director for the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin. Reference: Porsteinsson A, Isaacson R, Knox S, Sabbagh M, Rubino I. Diagnosis of early Alzheimer's disease: Clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371-386. © Eisai Inc. 2024. All Rights Reserved.AD-M2130 November 2024

Host: Jennifer Caudle, DO Guest: Lori Guyton, MD Guest: Douglas Scharre, MD Our understanding of the mechanisms underlying Alzheimer's disease is growing, and these advances can help inform diagnosis and management strategies. In fact, as our understanding of Alzheimer's disease evolves, our strategies to diagnose and manage the disease are changing to focus on early diagnosis and intervention.1 Joining Dr. Jennifer Caudle to discuss our current understanding of disease progression as well as the impact and benefit of diagnosing Alzheimer's disease early are Drs. Douglas Scharre and Lori Guyton. Dr. Scharre is the Director of the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin. Reference: Atri A. The Alzheimer's disease clinical spectrum: Diagnosis and management. Med Clin North Am. 2019;103:263-293. © Eisai Inc. 2024. All Rights Reserved.AD-M2123 November 2024

Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there's uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.

Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there's uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.

Host: Jennifer Caudle, DO Guest: A. Mark Fendrick, MD Approximately 40 percent of the eligible U.S. population are not up to date with their colorectal cancer (CRC) screenings, which inspired this study that was presented at Digestive Disease Week (DDW) 2024 to help eliminate the colonoscopy backlog with stool-based CRC screening options. To learn the details of this study and how we can incorporate the findings into practice, join Dr. Jennifer Caudle as she speaks with Dr. Mark Fendrick, Professor of Internal Medicine in the School of Medicine and Professor of Health Management and Policy in the School of Public Health at the University of Michigan.

Host: Jennifer Caudle, DO Guest: A. Mark Fendrick, MD Approximately 40 percent of the eligible U.S. population are not up to date with their colorectal cancer (CRC) screenings, which inspired this study that was presented at Digestive Disease Week (DDW) 2024 to help eliminate the colonoscopy backlog with stool-based CRC screening options. To learn the details of this study and how we can incorporate the findings into practice, join Dr. Jennifer Caudle as she speaks with Dr. Mark Fendrick, Professor of Internal Medicine in the School of Medicine and Professor of Health Management and Policy in the School of Public Health at the University of Michigan.

Host: Jennifer Caudle, DO Guest: Samuel R. Wilson, MD Sickle cell disease is among the most common inherited conditions globally, affecting more than seven million individuals worldwide.1-3 Given its prevalence, it is important to understand all of the complexities surrounding this disease. Joining Dr. Jennifer Caudle to discuss the pathophysiology, clinical presentation, burden, and unmet needs of sickle cell disease is Dr. Samuel R. Wilson, Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina School of Medicine. References: Sedrak A, Kondamudi NP. Sickle cell disease. StatPearls Publishing; 2023. Updated August 12, 2023. Accessed April 16, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482384/. Thomson AM, McHugh TA, Oron AP, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585-e599. doi:10.1016/S2352-3026(23)00118-7. CDC. Data & statistics on sickle cell disease. Centers for Disease Control and Prevention. Published May 2, 2022. Accessed April 16, 2024. https://www.cdc.gov/ncbddd/sicklecell/data.html/. Agios Pharmaceuticals, Inc. © 2024 All right reserved.SCD-US-0095 / June 2024

Host: Jennifer Caudle, DO Guest: Samuel R. Wilson, MD Sickle cell disease is among the most common inherited conditions globally, affecting more than seven million individuals worldwide.1-3 Given its prevalence, it is important to understand all of the complexities surrounding this disease. Joining Dr. Jennifer Caudle to discuss the pathophysiology, clinical presentation, burden, and unmet needs of sickle cell disease is Dr. Samuel R. Wilson, Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina School of Medicine. References: Sedrak A, Kondamudi NP. Sickle cell disease. StatPearls Publishing; 2023. Updated August 12, 2023. Accessed April 16, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482384/. Thomson AM, McHugh TA, Oron AP, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585-e599. doi:10.1016/S2352-3026(23)00118-7. CDC. Data & statistics on sickle cell disease. Centers for Disease Control and Prevention. Published May 2, 2022. Accessed April 16, 2024. https://www.cdc.gov/ncbddd/sicklecell/data.html/. Agios Pharmaceuticals, Inc. © 2024 All right reserved.SCD-US-0095 / June 2024

Host: Jennifer Caudle, DO Guest: Patricia A. Mangan, RN, MSN, APRN-BC The expansion of treatment options and strategies across the disease continuum is good news for patients who previously had few options; however, it can be a challenge for clinicians to stay up–to date in this very dynamic setting.

Host: Jennifer Caudle, DO Guest: Geoffrey B. Johnson, M.D., Ph.D. Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressing the PSMA target. In addition to that, the scan allows us to measure how much of the medication we get onto that cancer target and if it's going to be effective. Take a deep dive with Dr. Jennifer Caudle as she speaks with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota, who also presented this research at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.

Host: Jennifer Caudle, DO Guest: Geoffrey B. Johnson, M.D., Ph.D. Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressing the PSMA target. In addition to that, the scan allows us to measure how much of the medication we get onto that cancer target and if it's going to be effective. Take a deep dive with Dr. Jennifer Caudle as she speaks with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota, who also presented this research at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.

Host: Jennifer Caudle, DO Guest: Joyce O'Shaughnessy, MD The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.

Host: Jennifer Caudle, DO Guest: Joyce O'Shaughnessy, MD The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.

Host: Jennifer Caudle, DO Guest: Joyce O'Shaughnessy, MD The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.

Host: Jennifer Caudle, DO Guest: Jason Tremblay Due to a high prevalence of anemia in myelofibrosis, significant challenges could occur when diagnosing patients. But making a timely and accurate diagnosis is key, along with ensuring we're using the best therapeutic strategies. Learn more with Dr. Jennifer Caudle as she speaks with Dr. Douglas Tremblay, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.

Host: Jennifer Caudle, DO Guest: Sayantani Sindher, MD Recently, Omalizumab was studied in patients due to the avoidance of management and guidance when it comes to treating food allergies in children and adults. According to this doctor, approximately 45 percent of patients seen in his clinic have multi-food allergies that are not being met with current treatment options. So to explain his research, Dr. Jennifer Caudle is joined by Dr. Sayantani Sinder, Clinical Associate Professor of Medicine and Pediatric Allergy and Clinical Immunology Physician at Stanford Healthcare and Stanford Medicine Children's Health.

Host: Jennifer Caudle, DO Guest: Jason Tremblay Myelofibrosis is a heterogeneous disease and different hematologic manifestations, like anemia and thrombocytopenia, are variable based on the patients themselves. It might even be rare to see patients who experience myelofibrosis the same. So to take a deep dive into the treatment paradigm of this disease is Dr. Jennifer Caudle who will be speaking with Dr. Douglas Tremblay, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.

Host: Jennifer Caudle, DO Guest: Sarah Rutherford, MD Due to its strong response rates and manageable adverse events, CAR T-cell therapy is now considered the standard-of-care treatment for B-cell lymphomas in the second-line setting, which could lead to better outcomes for patients. Learn more about the efficacy and safety profile of CAR T-cell therapy with Dr. Jennifer Caudle and Dr. Sarah Rutherford, Assistant Professor of Medicine in the Division of Hematology-Oncology at Weill Cornell Medicine.

Host: Jennifer Caudle, DO Guest: Victoria A. Statler, MD, MSc Test-confirmed influenza outcomes provide a specific measure of influenza vaccine effectiveness (VE) and has helped to illustrate the potential benefit of cell-based versus egg-based vaccines.1 So what data support improved VE from cell-based flu vaccines versus egg-based vaccines? To learn more, join Dr. Jennifer Caudle as she speaks with Dr. Victoria A. Statler, Associate Professor of Pediatrics at the University of Louisville and the Director of the Pediatric Transplant and Immunocompromised Host service at Norton Children's Hospital. Reference: Stein AN, Mills C, McGovern, et al. Superior effectiveness of cell-based versus egg-based quadrivalent influenza vaccines against test-confirmed influenza over three consecutive seasons in the United States. Paper presented at: The Ninth European Scientific Working Group Influenza (ESWI) Influenza Conference; September 17-20, 2023: Valencia, Spain. USA-QIVc-23-0119 01/24

Host: Jennifer Caudle, DO Guest: Victoria A. Statler, MD, MSc Test-confirmed influenza outcomes provide a specific measure of influenza vaccine effectiveness (VE) and has helped to illustrate the potential benefit of cell-based versus egg-based vaccines.1 So what data support improved VE from cell-based flu vaccines versus egg-based vaccines? To learn more, join Dr. Jennifer Caudle as she speaks with Dr. Victoria A. Statler, Associate Professor of Pediatrics at the University of Louisville and the Director of the Pediatric Transplant and Immunocompromised Host service at Norton Children's Hospital. Reference: Stein AN, Mills C, McGovern, et al. Superior effectiveness of cell-based versus egg-based quadrivalent influenza vaccines against test-confirmed influenza over three consecutive seasons in the United States. Paper presented at: The Ninth European Scientific Working Group Influenza (ESWI) Influenza Conference; September 17-20, 2023: Valencia, Spain. USA-QIVc-23-0119 01/24

Host: Jennifer Caudle, DO Guest: Victoria A. Statler, MD, MSc Test-confirmed influenza outcomes provide a specific measure of influenza vaccine effectiveness (VE) and has helped to illustrate the potential benefit of cell-based versus egg-based vaccines.1 So what data support improved VE from cell-based flu vaccines versus egg-based vaccines? To learn more, join Dr. Jennifer Caudle as she speaks with Dr. Victoria A. Statler, Associate Professor of Pediatrics at the University of Louisville and the Director of the Pediatric Transplant and Immunocompromised Host service at Norton Children's Hospital. Reference: Stein AN, Mills C, McGovern, et al. Superior effectiveness of cell-based versus egg-based quadrivalent influenza vaccines against test-confirmed influenza over three consecutive seasons in the United States. Paper presented at: The Ninth European Scientific Working Group Influenza (ESWI) Influenza Conference; September 17-20, 2023: Valencia, Spain. USA-QIVc-23-0119 01/24

Host: Jennifer Caudle, DO Guest: Manpreet Mundi, MD Enteral nutrition intolerance is quite prevalent as it can be seen in up to 40 percent of patients who are tube fed. Due to the significant consequences of intolerance, there's an urgency to manage patients symptoms, and one option that's been shown to help is peptide-based tube feeding formulas. Joining Dr. Jennifer Caudle to talk about the management of enteral feeding intolerance with peptide-based tube feeding formulas is Dr. Manpreet Mundi, Professor of Medicine in the Department of Endocrinology at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota. All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé

Host: Jennifer Caudle, DO Guest: Manpreet Mundi, MD Enteral nutrition intolerance is quite prevalent as it can be seen in up to 40 percent of patients who are tube fed. Due to the significant consequences of intolerance, there's an urgency to manage patients symptoms, and one option that's been shown to help is peptide-based tube feeding formulas. Joining Dr. Jennifer Caudle to talk about the management of enteral feeding intolerance with peptide-based tube feeding formulas is Dr. Manpreet Mundi, Professor of Medicine in the Department of Endocrinology at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota. All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé

Host: Jennifer Caudle, DO Guest: Manpreet Mundi, MD Enteral nutrition intolerance is quite prevalent as it can be seen in up to 40 percent of patients who are tube fed. Due to the significant consequences of intolerance, there's an urgency to manage patients symptoms, and one option that's been shown to help is peptide-based tube feeding formulas. Joining Dr. Jennifer Caudle to talk about the management of enteral feeding intolerance with peptide-based tube feeding formulas is Dr. Manpreet Mundi, Professor of Medicine in the Department of Endocrinology at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota. All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé

Host: Jennifer Caudle, DO Guest: Rosanne Kho, MD To learn how Myfembree® (relugolix, estradiol, norethindrone acetate) could help address uterine fibroid-associated heavy menstrual bleeding or moderate to severe endometriosis pain in premenopausal women; listen to Dr. Jennifer Caudle and Dr. Rosanne Kho, Chair of the OB/GYN Department at the University of Arizona College of Medicine in Phoenix. Please scroll for Important Safety Information. Please see full Prescribing Information including BOXED WARNING here.

Host: Jennifer Caudle, DO Guest: Rosanne Kho, MD To learn how Myfembree® (relugolix, estradiol, norethindrone acetate) could help address uterine fibroid-associated heavy menstrual bleeding or moderate to severe endometriosis pain in premenopausal women; listen to Dr. Jennifer Caudle and Dr. Rosanne Kho, Chair of the OB/GYN Department at the University of Arizona College of Medicine in Phoenix. Please scroll for Important Safety Information. Please see full Prescribing Information including BOXED WARNING here.

Host: Jennifer Caudle, DO Guest: Katherine Bennett, MPH, RD, CLEC Caregivers and children often face challenges when trying to find a formula that's well-tolerated, and the burden of feeding intolerance extends to the healthcare system as well. Find out how blenderized whole food tube feeding whole food tube feeding formulas like Compleat Organic Blends can help address those challenges and benefit pediatric patients with Dr. Jennifer Caudle and Ms. Katherine Bennett, a registered dietitian at the Children's Hospital of Orange County in California. All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé

Host: Jennifer Caudle, DO Guest: Katherine Bennett, MPH, RD, CLEC Caregivers and children often face challenges when trying to find a formula that's well-tolerated, and the burden of feeding intolerance extends to the healthcare system as well. Find out how blenderized whole food tube feeding whole food tube feeding formulas like Compleat Organic Blends can help address those challenges and benefit pediatric patients with Dr. Jennifer Caudle and Ms. Katherine Bennett, a registered dietitian at the Children's Hospital of Orange County in California. All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé

Host: Jennifer Caudle, DO Guest: Katherine Bennett, MPH, RD, CLEC Caregivers and children often face challenges when trying to find a formula that's well-tolerated, and the burden of feeding intolerance extends to the healthcare system as well. Find out how blenderized whole food tube feeding whole food tube feeding formulas like Compleat Organic Blends can help address those challenges and benefit pediatric patients with Dr. Jennifer Caudle and Ms. Katherine Bennett, a registered dietitian at the Children's Hospital of Orange County in California. All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé

Host: Jennifer Caudle, DO Guest: Sana Raoof, MD, PhD There's a multi-cancer early detection test available that uses a targeted methylation, next-generation sequencing-based assay to detect and analyze cell-free DNA in the bloodstream, deploy machine learning to detect a cancer signal, and predict the likely origin of the signal.2 Explore the science behind this advancement that provides the highest specificity of any cancer screening tool1 with Dr. Jennifer Caudle and Dr. Sana Raoof, physician scientist at Memorial Sloan Kettering Cancer Center. References: Nadauld LD, McDonnell CH 3rd, Beer TM, et al. The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. Cancers (Basel). 2021;13(14):3501. Published 2021 Jul 13. doi:10.3390/cancers13143501 Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-759. doi:10.1016/j.annonc.2020.02.011

Host: Jennifer Caudle, DO Guest: Sana Raoof, MD, PhD There's a multi-cancer early detection test available that uses a targeted methylation, next-generation sequencing-based assay to detect and analyze cell-free DNA in the bloodstream, deploy machine learning to detect a cancer signal, and predict the likely origin of the signal.2 Explore the science behind this advancement that provides the highest specificity of any cancer screening tool1 with Dr. Jennifer Caudle and Dr. Sana Raoof, physician scientist at Memorial Sloan Kettering Cancer Center. References: Nadauld LD, McDonnell CH 3rd, Beer TM, et al. The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. Cancers (Basel). 2021;13(14):3501. Published 2021 Jul 13. doi:10.3390/cancers13143501 Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-759. doi:10.1016/j.annonc.2020.02.011

Host: Jennifer Caudle, DO Guest: David Saperstein, MD When it comes to treating chronic inflammatory demyelinating polyneuropathy (CIDP) with subcutaneous immunoglobulin (SCIG), the patient can be trained by a professional to administer the treatment themselves. So what counseling strategies can we use to help patients successfully transition from intravenous to SCIG therapy? Join Dr. Jennifer Caudle as she gains insights from Dr. David Saperstein, Director of the Center for Complex Neurology, EDS, and POTS in Phoenix, Arizona, and Associate Professor of Clinical Neurology at the University of Arizona College of Medicine.

Host: Jennifer Caudle, DO Guest: Michelle Kincaid, MD The largest study to date on 4F-PCC was conducted as an FDA postmarketing requirement in partnership between Kaiser Permanente and CSL Behring. The purpose of this long-term study was to compare the 45-day risk of thromboembolic events and all-cause mortality in adults with warfarin-associated major bleeding after treatment with KCENTRA®, Prothrombin Complex Concentrate (Human), or plasma. Take a deep dive into the data with Dr. Jennifer Caudle as she speaks with Dr. Michelle Kincaid, Trauma Surgeon and Director of Surgical Critical Care at Ohio Health Grant Medical Center in Columbus.

Host: Jennifer Caudle, DO Guest: Michelle Kincaid, MD The largest study to date on 4F-PCC was conducted as an FDA postmarketing requirement in partnership between Kaiser Permanente and CSL Behring. The purpose of this long-term study was to compare the 45-day risk of thromboembolic events and all-cause mortality in adults with warfarin-associated major bleeding after treatment with KCENTRA®, Prothrombin Complex Concentrate (Human), or plasma. Take a deep dive into the data with Dr. Jennifer Caudle as she speaks with Dr. Michelle Kincaid, Trauma Surgeon and Director of Surgical Critical Care at Ohio Health Grant Medical Center in Columbus.

Host: Jennifer Caudle, DO Guest: Michelle Kincaid, MD The largest study to date on 4F-PCC was conducted as an FDA postmarketing requirement in partnership between Kaiser Permanente and CSL Behring. The purpose of this long-term study was to compare the 45-day risk of thromboembolic events and all-cause mortality in adults with warfarin-associated major bleeding after treatment with KCENTRA®, Prothrombin Complex Concentrate (Human), or plasma. Take a deep dive into the data with Dr. Jennifer Caudle as she speaks with Dr. Michelle Kincaid, Trauma Surgeon and Director of Surgical Critical Care at Ohio Health Grant Medical Center in Columbus.

Host: Jennifer Caudle, DO Guest: Ravi Jhaveri, MD Influenza vaccines have prevented between 39,000 and 105,000 hospitalizations and between 3,700 and 9,800 deaths each year over the last 10 years in the United States alone.1 But many challenges still exist in the traditional egg-based influenza vaccine manufacturing process. To explore how cell-based vaccines, an option that uses an alternative manufacturing approach, could help address those challenges and the overall influenza burden, Dr. Jennifer Caudle speaks with Dr. Ravi Jhaveri, Division Head of Pediatric Infectious Diseases at the Ann & Robert H. Lurie Children's Hospital of Chicago. References:1. Centers for Disease Control and Prevention. Past seasons estimated influenza disease burden averted by vaccination. https://www.cdc.gov/flu/vaccines-work/past-burden-averted-est.html. Accessed April 8, 2022. USA-QIVc-23-0038 06/23

Host: Jennifer Caudle, DO Guest: Ravi Jhaveri, MD Influenza vaccines have prevented between 39,000 and 105,000 hospitalizations and between 3,700 and 9,800 deaths each year over the last 10 years in the United States alone.1 But many challenges still exist in the traditional egg-based influenza vaccine manufacturing process. To explore how cell-based vaccines, an option that uses an alternative manufacturing approach, could help address those challenges and the overall influenza burden, Dr. Jennifer Caudle speaks with Dr. Ravi Jhaveri, Division Head of Pediatric Infectious Diseases at the Ann & Robert H. Lurie Children's Hospital of Chicago. References:1. Centers for Disease Control and Prevention. Past seasons estimated influenza disease burden averted by vaccination. https://www.cdc.gov/flu/vaccines-work/past-burden-averted-est.html. Accessed April 8, 2022. USA-QIVc-23-0038 06/23

Host: Jennifer Caudle, DO Guest: Jeran Wadlow Guest: Josh Elmassian, MBA Allergan Medical Institute® has taken a personalized approach to training HCPs in medical aesthetics with the launch of AMI Online. Discover multiple online courses spanning the Allergan Aesthetics portfolio, including content on JUVÉDERM® VOLUX® XC. Experience how AMI Online's evidence-based and progressive training curricula can educate and empower the aesthetics community. Join Dr Jennifer Caudle as she speaks with Jeran Wadlow, Associate Director, Digital at Allergan Medical Institute® in Irvine, California, and Josh Elmassian, Director of JUVÉDERM® US Commercial Business and Marketing at Allergan Aesthetics, in Irvine, California. © 2023 AbbVie. All rights reserved. JUVÉDERM and its design are trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates. All other trademarks are the property of their respective owners. PRT162857 06/23

Host: Jennifer Caudle, DO Guest: Jeran Wadlow Guest: Josh Elmassian, MBA Allergan Medical Institute® has taken a personalized approach to training HCPs in medical aesthetics with the launch of AMI Online. Discover multiple online courses spanning the Allergan Aesthetics portfolio, including content on JUVÉDERM® VOLUX® XC. Experience how AMI Online's evidence-based and progressive training curricula can educate and empower the aesthetics community. Join Dr Jennifer Caudle as she speaks with Jeran Wadlow, Associate Director, Digital at Allergan Medical Institute® in Irvine, California, and Josh Elmassian, Director of JUVÉDERM® US Commercial Business and Marketing at Allergan Aesthetics, in Irvine, California. © 2023 AbbVie. All rights reserved. JUVÉDERM and its design are trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates. All other trademarks are the property of their respective owners. PRT162857 06/23

Host: Jennifer Caudle, DO Guest: Tamera A. Paczos, MD, FACOG, FACP The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories. COBAS and CINTEC are trademarks of Roche.All other product names and trademarks are the property of their respective owners. 02/23

Host: Jennifer Caudle, DO Guest: Tamera A. Paczos, MD, FACOG, FACP The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories. COBAS and CINTEC are trademarks of Roche.All other product names and trademarks are the property of their respective owners. 02/23

Host: Jennifer Caudle, DO Guest: Tamera A. Paczos, MD, FACOG, FACP The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories. COBAS and CINTEC are trademarks of Roche.All other product names and trademarks are the property of their respective owners. 02/23

Host: Jennifer Caudle, DO Guest: Diane M. Harper, MD, MPH, MS There are several testing methods available for cervical cancer screening, such as co-testing and primary HPV testing. So what are some of the most prominent benefits and limitations of these and other testing approaches? Joining Dr. Jennifer Caudle to break down the latest advancements in cervical cancer screening is Dr. Diane Harper, a Professor in the Departments of Family Medicine and Obstetrics and Gynecology at the University of Michigan.

Host: Jennifer Caudle, DO Guest: Majed Refaai, MD While VKA-related GI bleeds are common, clinicians need to be aware of the severity of the bleed, especially in cases of hemodynamic instability. To get a better understanding of the impact of this severity, Dr. Majed Refaai from the University of Rochester Medical Center shares insights on these life-threatening bleeds.

Host: Jennifer Caudle, DO Guest: Carolyn Bridges, MD We all know that influenza vaccinations can help prevent serious infections and save lives. But how often do you consider the underrecognized benefits of these vaccines—like how influenza vaccinations can be a cost-effective solution for both patients and the entire healthcare system? Joining Dr. Jennifer Caudle to discuss these underrecognized benefits and how we can educate patients about the benefits of influenza vaccination is Dr. Carolyn Bridges, Director of Adult Immunizations at Immunize.org.

Host: Jennifer Caudle, DO Guest: Maitreyi Raman , MD, MSc, FRCPC Diet and nutrition is known to play a large role in the onset and treatment of IBD. So what were some of the trending sessions focusing on diet and nutrition at the 2022 Crohn's & Colitis Congress? Join Dr. Jennifer Caudle as she speaks with Dr. Maitreyi Raman to explore the latest research advancements in diet therapies.

Host: Jennifer Caudle, DO Guest: Maitreyi Raman , MD, MSc, FRCPC Diet and nutrition is known to play a large role in the onset and treatment of IBD. So what were some of the trending sessions focusing on diet and nutrition at the 2022 Crohn's & Colitis Congress? Join Dr. Jennifer Caudle as she speaks with Dr. Maitreyi Raman to explore the latest research advancements in diet therapies.